CoChat

The economic value of targeting aging

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.

Abstract

Developments in life expectancy and the growing emphasis on biological and ‘healthy’ aging raise a number of important questions for health scientists and economists alike. Is it preferable to make lives healthier by compressing morbidity, or longer by extending life? What are the gains from targeting aging itself compared to efforts to eradicate specific diseases? Here we analyze existing data to evaluate the economic value of increases in life expectancy, improvements in health and treatments that target aging. We show that a compression of morbidity that improves health is more valuable than further increases in life expectancy, and that targeting aging offers potentially larger economic gains than eradicating individual diseases. We show that a slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion. Ultimately, the more progress that is made in improving how we age, the greater the value of further improvements.

Overview

CoChat Summary

TL;DR

Using a value-of-statistical-life economic model calibrated to US data, the paper finds that health-improving compression of morbidity is more valuable than further life extension, and that targeting aging itself yields larger economic gains than eradicating individual diseases. A slowdown in aging that adds 1 year of life expectancy is worth US$37.6 trillion, and one adding 10 years is worth US$366.8 trillion.

Key findings

  • The willingness to pay for an extra year of healthy life expectancy always exceeds that for an extra year of life expectancy; individuals prefer compression of morbidity over further life extension.
  • A 2017 slowdown in aging producing a 1-year increase in life expectancy is worth US$37.6 trillion total (US$29.7 trillion for those alive in 2017 and US$7.9 trillion for unborn generations); a 10-year increase is worth US$366.8 trillion (US$291.9 trillion and US$74.8 trillion, respectively). At a 2% interest rate, the 10-year gain is US$7.2 trillion annually, or 33.6% of 2019 GDP.
  • Metformin, used as an example of targeting aging, often matches or exceeds the value of eradicating cancer, dementia, or cardiovascular diseases; treatment starting at age 75 raises life expectancy at birth by 2.9 years and at age 80 by 4.3 years, with healthy life expectancy gains of 1.7–2.5 years.
  • Targeting aging creates a virtuous circle: the more society improves how it ages, the greater the aggregate economic value of further improvements, because gains rise with the average age of society and the number of older people.

Methods

  • The authors use an economic model based on Murphy and Topel, calibrated to current US data, in which optimizing individuals choose consumption, hours worked, and leisure; willingness to pay is measured via value of statistical life, incorporating both quantity and quality of remaining life.
  • Demographic inputs include a Gompertz survival function, a health deficit function, and 2017 US Census population structure and birth rates; baseline life expectancy at birth is 78.9 years and healthy life expectancy is 68.5 years, with adult VSL set at US$11.5 million for ages 25–65.
  • Simulations cover life extension (Struldbrugg), compression of morbidity (Dorian Gray), slowing aging (Peter Pan), reversing aging (Wolverine), and metformin effects based on a study of 41,204 men with diabetes; aggregate WTP sums age-specific values using census data.

Limitations

  • The paper states that metformin’s efficacy awaits confirmation from large trials such as TAME; the metformin estimates rely on a study of 41,204 men over 65 with diabetes, so factors may not accurately capture effects for women, non-diabetics, or those under 65, and metformin may have less impact at higher ages.
  • The paper states that estimates abstract from inequalities in health and income; allowing for health inequalities likely increases aggregate gains, while income inequality raises distributional issues, and dollar WTP values are sensitive to model calibration though relative treatment rankings are not.
  • Evident from the text: results are simulation-based rather than direct empirical estimates, depend on VSL and utility assumptions, and the Wolverine scenario requires additional auxiliary assumptions; aggregate projections also assume zero net immigration and current birth and mortality rates.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s43587-021-00080-0

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Survival functions under rectangularization and improvement in lifespan. Three different survival functions (probability of surviving from birth to different ages). Baseline is a standard Gompertz–Makeham survival function calibrated to 2019 US data. The rectangularization curve shows a survival function in which improvements in LE are achieved through compressing morbidity. The lifespan improvement curve shows a survival function in which improvements arise through elongation of the aging process. Source data
Fig. 1 Survival functions under rectangularization and improvement in lifespan. Three different survival functions (probability of surviving from birth to different ages). Baseline is a standard Gompertz–Makeham survival function calibrated to 2019 US data. The rectangularization curve shows a survival function in which improvements in LE are achieved through compressing morbidity. The lifespan improvement curve shows a survival function in which improvements arise through elongation of the aging process. Source dataCC BY · PubMed Central
Fig. 2 WTP by year of life for metformin treatment started at age 75. The value for each year (by age) of improvements in the incidence of various diseases under simulated impact of metformin. Sum of separate effects, the total of each individual effect; Total effect, the overall value for each year of health improvements attributed to metformin. Solid lines represent WTP for each of the five comorbidities separately. Source data
Fig. 2 WTP by year of life for metformin treatment started at age 75. The value for each year (by age) of improvements in the incidence of various diseases under simulated impact of metformin. Sum of separate effects, the total of each individual effect; Total effect, the overall value for each year of health improvements attributed to metformin. Solid lines represent WTP for each of the five comorbidities separately. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 9 Not checked · 52 Own results and interpretations

34 more claims

Create a free account to see all 68 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 7
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Barzilai, N. Age Later: Health Span, Life Span, and the New Science of Longevity (St Martin’s Press, 2020).

Cited by

See all 274

Metadata

Authors
Scott, A. J., Ellison, M., & Sinclair, D. A.
Affiliations
  • London Business School (GB)
  • University of Oxford (GB)
  • Harvard University (US)
Corresponding author
Scott, Andrew J.
Venue
Nature Aging
Published
2021-07-05
Volume
1
Issue
7
Pages
616-623
ISSN
2662-8465 (ISSN-L)
OpenAlex
W3180012192
Cited by
267
References
34
Citations by year
2026: 64 · 2025: 64 · 2024: 59 · 2023: 40 · 2022: 28 · 2021: 12
FWCI
40.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Aging (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • London Business School Research Online (London Business School) (acceptedVersion, cc-by)
Funders
  • RCUK | Economic and Social Research Council (T002204)
  • Oxford University | John Fell Fund, University of Oxford
  • Glenn Foundation for Medical Research
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Demography › Insurance, Mortality, Demography, Risk Management
Keywords
aging, life expectancy, compression of morbidity, healthy aging, anti-aging interventions, disease eradication, health gains, economic valuation of health
MeSH terms
Health Status, Life Expectancy, Morbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The economic value of targeting aging. https://app.cochat.ai/papers/10.1038/s43587-021-00080-0
The paper
Scott, A. J., Ellison, M., & Sinclair, D. A. (2021). The economic value of targeting aging. Nature Aging. https://doi.org/10.1038/s43587-021-00080-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.